Cell-mediated immunity against HGP-30, a group-specific peptide of HIV p17 in individuals infected with the AIDS virus. 1992

A Willer, and A Achour, and J P Mbika, and K Laaroubi, and A Lachgar, and A Nihrane, and O Picard, and P H Naylor, and P S Sarin, and A L Goldstein
Université Pierre et Marie Curie, Paris, France.

HGP-30, the synthetic peptide analogue and active component in an HIV-1 (human immunodeficiency virus, type 1) p 17 core-based experimental vaccine, has previously been shown to induce cytotoxic and helper T-lymphocyte responses. In order to further define the T-helper cell responses which are known to play a role in enhancing the immunological response to foreign antigens, we studied the response of individuals infected with HIV to HGP-30 at various stages of disease progression. We have investigated the proliferative cellular response of peripheral blood mononuclear cells (PBMCs) derived from individuals infected with HIV-1 to HGP-30. We have found a PBMC proliferative response to HGP-30 in 40% of the healthy seroconverted patients, in 35% of the CDC stage III patients and in 18% of the CDC stage IV patients. There was no correlation between the proliferative response to HGP-30 and other antigens such as HIV-like proteins or tetanus toxoid not to CD4 cell count. HLA-DR typing revealed the possible presentation of HGP-30 by several different class II molecules. Since these class II molecules occur frequently in the general population, HGP-30 appears to contain broadly reactive epitopes and thus is not restricted as are many peptide vaccines. Due to its broad reactivity and extreme conservation in many HIV-1 strains. HGP-30 is one of the promising candidates for inclusion as a subunit vaccine against HIV-1.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D005802 Genes, MHC Class II Genetic loci in the vertebrate major histocompatibility complex that encode polymorphic products which control the immune response to specific antigens. The genes are found in the HLA-D region in humans and include H-2M, I-A, and I-E loci in mice. Class II Genes,Genes, Class II,Genes, HLA Class II,MHC Class II Genes,Class II Gene,Gene, Class II
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte
D013745 Tetanus Toxoid Tetanus Vaccine,Toxoid, Tetanus,Vaccine, Tetanus
D015488 HIV Antigens Antigens associated with specific proteins of the human adult T-cell immunodeficiency virus (HIV); also called HTLV-III-associated and lymphadenopathy-associated virus (LAV) antigens. AIDS Antigens,HIV-Associated Antigens,HTLV-III Antigens,HTLV-III-LAV Antigens,LAV Antigens,Lymphadenopathy-Associated Antigens,T-Lymphotropic Virus Type III Antigens, Human,HIV Associated Antigens,HTLV III Antigens,HTLV III LAV Antigens,Lymphadenopathy Associated Antigens,T Lymphotropic Virus Type III Antigens, Human,Antigens, AIDS,Antigens, HIV,Antigens, HIV Associated,Antigens, HIV-Associated,Antigens, HTLV III,Antigens, HTLV-III,Antigens, HTLV-III-LAV,Antigens, LAV,Antigens, Lymphadenopathy Associated,Antigens, Lymphadenopathy-Associated,Associated Antigens, HIV,Associated Antigens, Lymphadenopathy,III Antigens, HTLV
D015704 CD4 Antigens 55-kDa antigens found on HELPER-INDUCER T-LYMPHOCYTES and on a variety of other immune cell types. They are members of the immunoglobulin supergene family and are implicated as associative recognition elements in MAJOR HISTOCOMPATIBILITY COMPLEX class II-restricted immune responses. On T-lymphocytes they define the helper/inducer subset. T4 antigens also serve as INTERLEUKIN-15 receptors and bind to the HIV receptors, binding directly to the HIV ENVELOPE PROTEIN GP120. Antigens, CD4,CD4 Molecule,CD4 Receptor,CD4 Receptors,Receptors, CD4,T4 Antigens, T-Cell,CD4 Antigen,Receptors, Surface CD4,Surface CD4 Receptor,Antigen, CD4,Antigens, T-Cell T4,CD4 Receptor, Surface,CD4 Receptors, Surface,Receptor, CD4,Surface CD4 Receptors,T-Cell T4 Antigens,T4 Antigens, T Cell
D054301 gag Gene Products, Human Immunodeficiency Virus Proteins encoded by the GAG GENE of the HUMAN IMMUNODEFICIENCY VIRUS. gag Gene Products, HIV,gag Proteins, Human Immunodeficiency Virus

Related Publications

A Willer, and A Achour, and J P Mbika, and K Laaroubi, and A Lachgar, and A Nihrane, and O Picard, and P H Naylor, and P S Sarin, and A L Goldstein
September 1990, Proceedings of the National Academy of Sciences of the United States of America,
A Willer, and A Achour, and J P Mbika, and K Laaroubi, and A Lachgar, and A Nihrane, and O Picard, and P H Naylor, and P S Sarin, and A L Goldstein
May 1987, Proceedings of the National Academy of Sciences of the United States of America,
A Willer, and A Achour, and J P Mbika, and K Laaroubi, and A Lachgar, and A Nihrane, and O Picard, and P H Naylor, and P S Sarin, and A L Goldstein
June 1998, AIDS research and human retroviruses,
A Willer, and A Achour, and J P Mbika, and K Laaroubi, and A Lachgar, and A Nihrane, and O Picard, and P H Naylor, and P S Sarin, and A L Goldstein
January 1991, International journal of immunopharmacology,
A Willer, and A Achour, and J P Mbika, and K Laaroubi, and A Lachgar, and A Nihrane, and O Picard, and P H Naylor, and P S Sarin, and A L Goldstein
August 1992, AIDS research and human retroviruses,
A Willer, and A Achour, and J P Mbika, and K Laaroubi, and A Lachgar, and A Nihrane, and O Picard, and P H Naylor, and P S Sarin, and A L Goldstein
May 1995, Cellular and molecular biology (Noisy-le-Grand, France),
A Willer, and A Achour, and J P Mbika, and K Laaroubi, and A Lachgar, and A Nihrane, and O Picard, and P H Naylor, and P S Sarin, and A L Goldstein
October 1989, Journal of theoretical biology,
A Willer, and A Achour, and J P Mbika, and K Laaroubi, and A Lachgar, and A Nihrane, and O Picard, and P H Naylor, and P S Sarin, and A L Goldstein
March 2006, AIDS research and human retroviruses,
A Willer, and A Achour, and J P Mbika, and K Laaroubi, and A Lachgar, and A Nihrane, and O Picard, and P H Naylor, and P S Sarin, and A L Goldstein
January 1982, Springer seminars in immunopathology,
A Willer, and A Achour, and J P Mbika, and K Laaroubi, and A Lachgar, and A Nihrane, and O Picard, and P H Naylor, and P S Sarin, and A L Goldstein
August 2005, The Journal of infectious diseases,
Copied contents to your clipboard!